Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes.
At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
Company Details
- Employees
- 70
- Founded
- -
- Address
- 700 Dexter Ave N,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.outpacebio.com
- HQ
- Seattle, Washington
Outpace Bio Questions
Outpace Bio's website is http://www.outpacebio.com
Outpace Bio's LinkedIn profile is https://www.linkedin.com/company/outpace-bio
Outpace Bio has
70 employees.
View email and phone details for 70
employees at Outpace Bio.
Outpace Bio's industry is
Biotechnology Research
Outpace Bio's top competitors are
Umoja Biopharma,
Parse Biosciences,
Shape Therapeutics Inc.,
A-Alpha Bio,
Jade Biosciences,
Monod Bio,
Lumen Bioscience,
Curi Bio,
Shinobi Therapeutics,
Sana Biotechnology, Inc..
Outpace Bio's categories are Biotechnology Research
Outpace Bio's founding year is 2020
